SEC Form 4 · accession 0001209191-17-064372
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dawn Carter Bir
Officer — VP, Chief Commercial Officer
Period of report
Dec 6, 2017
Accepted (ET)
Dec 7, 2017 · 3:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1,F2 | $24.75 | Dec 6, 2017 | A | 71,300 | A | — | Dec 6, 2027 | Class B common stock | 71,300 | 71,300 | D |
Explanation of responses
- F1The options vest in sixteen equal quarterly installments beginning on March 6, 2018, subject to continued service through each vesting date.
- F2The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.